Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis.

By Shanshan Li, H. Shin, E. Ding, R. V. van Dam. Journal of the American Medical Association (JAMA), 2009

1,027 citations recorded by the source corpus.

CONTEXT The association of obesity with development of type 2 diabetes may be partly mediated by altered secretion of adipokines by adipose tissue. Greater adiposity down-regulates secretion of adiponectin, an adipokine with anti-inflammatory and insulin-sensitizing properties. The strength and consistency of the relation between plasma adiponectin and risk of type 2 diabetes is unclear. OBJECTIVE To systematically review prospective studies of the association of plasma adiponectin levels and risk of type 2 diabetes. DATA SOURCES A systematic search of the MEDLINE, EMBASE, and Science Citation Index Expanded databases using adiponectin and diabetes and various synonyms and reference lists of retrieved articles up to April 10, 2009. STUDY SELECTION We included prospective studies with plasma adiponectin levels as the exposure and incidence of type 2 diabetes as the outcome variable. DATA EXTRACTION Two reviewers independently extracted data and assessed study quality. Generalized least-squares trend estimation was used to assess dose-response relationships. Pooled relative risks and 95% confidence intervals were calculated using random-effects models to incorporate between-study variation. RESULTS Thirteen prospective studies with a total of 14 598 participants and 2623 incident cases of type 2 diabetes were included in the meta-analysis. Higher adiponectin levels were monotonically associated with a lower risk of type 2 diabetes. The relative risk of type 2 diabetes was 0.72 (95% confidence interval, 0.67-0.78) per 1-log microg/mL increment in adiponectin levels. This inverse association was consistently observed in whites, East Asians, Asian Indians, African Americans, and Native Americans and did not differ by adiponectin assay, method of diabetes ascertainment, duration of follow-up, or proportion of women. The estimated absolute risk difference (cases per 1000 person-years) per 1-log microg/mL increment in adiponectin levels was 3.9 for elderly Americans and 30.8 for Americans with impaired glucose tolerance. CONCLUSION Higher adiponectin levels are associated with a lower risk of type 2 diabetes across diverse populations, consistent with a dose-response relationship.

Subfields: Cardiology and Cardiovascular Medicine, Emergency Medicine, Epidemiology

View Paper: https://www.semanticscholar.org/paper/83a7dbeaaf2e921bcee3d85063c41e7fde09cbad

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. André Tchernof
2. K. Walsh
3. P. Scherer
4. J. Despres
5. N. Ouchi
6. Haiming Cao
7. M. Blüher

In Epidemiology

1. André Tchernof
2. K. Walsh
3. P. Scherer
4. N. Ouchi
5. M. Roden
6. J. Despres
7. H. Kwon
8. J. Pessin

Citations in the corpus

• Adipokines Mediate Inflammation and Insulin Resistance (2013, background): “As pro-inflammatory factors such as TNF-α, IL-6, ROS, and hypoxia suppress the expression of adiponectin in adipocytes, adiponectin levels are decreased in obese rodents and humans (Li et al., 2009).”
• Identification of Serum Metabolites Associated With Risk of Type 2 Diabetes Using a Targeted Metabolomic Approach (2013, background): “A number of biomarkers have been proposed as indicators for the estimation of T2D risk, such as fasting plasma glucose and glycated hemoglobin A1c (HbA1c) (2), triglycerides (3), HDL cholesterol (4), inflammatory markers (5), adiponectin (5,6), liver enzymes (7), and fetuin-A (8).”
• Pathophysiology of human visceral obesity: an update. (2013, background): “It appears clear, however, that low adiponectinemia predicts an increased risk of type 2 diabetes (322, 529).”
• Obesity and inflammation: the linking mechanism and the complications (2016, neutral): “[131] Meta-analysis T2DM”
• Trends in insulin resistance: insights into mechanisms and therapeutic strategy (2022, result): “In contrast to other adipokines, plasma adiponectin levels were reduced by pro-inflammatory factors like TNF-α, IL-6, ROS, and hypoxia in animal models of obesity and IR.(139,140) Adiponectin activates the AMPK and PPAR-α signaling pathways through adiponectin receptor 1 (AdipoR1) and AdipoR2 respec”
• Adipocytokines in Obesity and Metabolic Disease (2014, neutral): “(Li et al. 2009).”
• Adipokines in inflammation and metabolic disease (2011, background): “; second, plasma adiponectin levels are decreased in patients with type 2 diabetes; and third, high adiponectin levels are associated with a lower risk for developing type 2 diabete”
• Adiponectin: mechanistic insights and clinical implications (2012, background): “Furthermore, cohort studies in many different groups have consistently shown an inverse relationship between adiponectin levels and the presence of (or propensity to develop) glucose intolerance and type 2 diabetes [19].”